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Abstract 
In recent years remarkable progress has been made towards the understanding of proposed 
hallmarks of cancer development and treatment. However with its increasing incidence, the 
clinical management of cancer continues to be a challenge for the 21
st century. Treatment 
modalities  comprise  of  radiation  therapy,  surgery,  chemotherapy,  immunotherapy  and 
hormonal therapy. Radiation therapy remains an important component of cancer treatment 
with approximately 50% of all cancer patients receiving radiation therapy during their course 
of illness; it contributes towards 40% of curative treatment for cancer. The main goal of ra-
diation therapy is to deprive cancer cells of their multiplication (cell division) potential. 
Celebrating a century of advances since Marie Curie won her second Nobel Prize for her 
research into radium, 2011 has been designated the Year of Radiation therapy in the UK. Over 
the last 100 years, ongoing advances in the techniques of radiation treatment and progress 
made in understanding the biology of cancer cell responses to radiation will endeavor to 
increase the survival and reduce treatment side effects for cancer patients. In this review, 
principles, application and advances in radiation therapy with their biological end points are 
discussed. 
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Introduction 
Cancer remains leading cause of death globally. 
The  International  Agency  for  Research  on  Cancer 
(IARC)  recently  estimated  that  7.6  million  deaths 
worldwide were due to cancer with 12.7 million new 
cases per year being reported worldwide. A signifi-
cant proportion of this burden is borne by developing 
countries;  63%  of  cancer  deaths  are  reported  to  be 
from developing countries [1, 2, 3]. Cancer is a mul-
tigenic and multicellular disease that can arise from 
all cell types and organs with a multi-factorial etiolo-
gy.  Hanahan  and  Weinberg  [4]  have  identified  six 
cancer cell phenotypes or  hallmarks of cancer: cells 
with unlimited proliferative potential, environmental 
independence  for  growth,  evasion  of  apoptosis,  an-
giogenesis, invasion and metastasis to different parts 
of  body.  If  uncontrolled  cell  growth  or  metastatic 
spread occurs it will result in death of the individual 
[5].  The  past  decade  has  witnessed  a  considerable 
progress towards the treatment and understanding of 
the earlier proposed hallmarks of cancer [6] and to-
gether with advances in early detection and in the 
various  treatment  modalities,  many  cancers  have 
become curable [7]. 
After the discovery of X-rays in 1895, by Wilhelm 
Conrad Röntgen from Germany its clinical usefulness, 
as a means of cancer treatment was first appreciated. 
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It is also one hundred years ago that Marie Curie won 
a  second  Nobel  Prize  for  her  research  into  radium, 
establishing her position as a pioneer in the field of 
radiation therapy. To mark this, 2011 has been desig-
nated the Year of Radiation therapy in the UK, cele-
brating a century of advances. Since that time, radia-
tion therapy has developed into a recognized medical 
specialty with Radiation Oncology being a discipline 
in  which  various  health  and  science  professionals 
from numerous disciplines work together. Along with 
surgery and chemotherapy, radiation therapy or ra-
diotherapy  remains  an  important  modality  used  in 
cancer treatment being a highly cost effective single 
modality treatment accounting about only 5% of the 
total  cost  of  cancer  care  [8].  Furthermore,  approxi-
mately 50% of all cancer patients will receive radiation 
therapy during their course of illness [9, 10] with an 
estimation  that  radiation  therapy  contributes  to 
around 40% towards curative treatment [11]. Rapid 
progress in this field continues to be boosted by ad-
vances  in  imaging  techniques,  computerized  treat-
ment planning systems, radiation treatment machines 
(with improved X-ray production and treatment de-
livery) as well as improved understanding of the ra-
diobiology of radiation therapy [12]. 
Principles of radiation therapy  
Radiation is a physical agent, which is used to 
destroy cancer cells. The radiation used is called ion-
izing  radiation  because  it  forms  ions  (electrically 
charged particles) and deposits energy in the cells of 
the tissues it passes through. This deposited energy 
can kill cancer cells or cause genetic changes resulting 
in cancer cell death.  
High-energy radiation damages genetic material 
(deoxyribonucleic  acid,  DNA)  of  cells  and  thus 
blocking their ability to divide and proliferate further 
[13]. Although radiation damages both normal cells as 
well as cancer cells, the goal of radiation therapy is to 
maximize the radiation dose to abnormal cancer cells 
while minimizing exposure to normal cells, which is 
adjacent  to  cancer  cells  or  in  the  path  of  radiation. 
Normal cells usually can repair themselves at a faster 
rate  and  retain  its  normal  function  status  than  the 
cancer cells. Cancer cells in general are not as efficient 
as  normal  cells  in  repairing  the  damage  caused  by 
radiation treatment resulting in differential cancer cell 
killing [10].  
Radiation can be given with the intent of cure as 
well as being used as a very effective modality of pal-
liative treatment to relieve patients from symptoms 
caused by the cancer. Further indications of radiation 
therapy  include  combination  strategies  with  other 
treatment modalities such as surgery, chemotherapy 
or immunotherapy. If used before surgery (neoadju-
vant therapy), radiation will aim to shrink the tumor. 
If used after surgery (adjuvant therapy), radiation will 
destroy microscopic tumor cells that may have been 
left behind. It is well known that tumors differ in their 
sensitivity to radiation treatment. Table 1 shows a list 
of common cancers treated with radiation therapy. 
There are two ways to deliver radiation to the 
location of the cancer. External beam radiation is de-
livered from outside the body by aiming high-energy 
rays  (photons,  protons  or  particle  radiation)  to  the 
location of the tumor. This is the most common ap-
proach  in  the  clinical  setting.  Internal  radiation  or 
brachytherapy is delivered from inside the body by 
radioactive  sources,  sealed  in  catheters  or  seeds  di-
rectly into the tumor site. This is used particularly in 
the  routine  treatment  of  gynecological  and  prostate 
malignancies as well  as  in situations  where retreat-
ment is indicated, based on its short range effects. 
 
 
Table 1. Examples of cancers treated with radiation 
therapy. 
Early cancers curable with radi-
ation therapy alone             
Cancers curable with radiation 
therapy in combination with 
other modalities 
Skin cancers (Squamous and 
Basel cell) 
Breast carcinomas 
Prostate carcinomas  Rectal and anal carcinomas 
Lung carcinomas (non-small 
cell) 
Local advanced cervix carcino-
mas 
Cervix carcinomas  Locally advanced head and neck 
carcinomas 
Lymphomas (Hodgkin’s and 
low grade Non-Hodgkin’s) 
Locally advanced lung carcino-
mas 
Head and neck carcinomas  Advanced lymphomas 
  Bladder carcinomas 
  Endometrial carcinomas 
  CNS tumors 
  Soft tissue sarcomas 
  Pediatric tumors 
 
 
Radiation therapy techniques 
Fractionation 
Radiation therapy delivered in a fractionated re-
gime is based on the differing radiobiological proper-
ties of cancer and various normal tissues. These re-
gimes in general amplify  the survival advantage of 
normal  tissues  over  cancer  cells,  largely  based  on 
better sublethal damage repair of radiation damage in 
normal cells as compared to cancer cells. Normal cells Int. J. Med. Sci. 2012, 9 
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proliferate  relatively  more  slowly  compared  to  the 
rapidly proliferating cancer cells and therefore have 
time to repair damage before replication. Initial ob-
servations  of  the  effects  of  fractionated  radiation 
therapy in the 1920s eventually led to the develop-
ment  of  regimes  comparing  different  treatment 
schedules  based  on  total  dose,  number  of  fractions 
and overall treatment time [14]. Current regimes are 
based on  the  more refined linear-quadratic formula 
which addresses the time-dose factors for individual 
tumor types and normal tissues [15]. A typical radia-
tion therapy regime now consists of daily fractions of 
1.5 to 3Gy given over several weeks.  
Technological advances 
The goal of radiotherapy is to deliver as much 
dose  to  the  tumour  whilst  sparing  normal  tissue. 
Technological  advances  incorporating  new  imaging 
modalities, more powerful computers and software, 
and  new  delivery  systems  such  as  advanced  linear 
accelerators have helped achieve this. 
3D Conformal radiotherapy (3DCRT) 
2D  radiation  therapy  using  rectangular  fields 
based  on  plain  X-ray  imaging  has  largely  been  re-
placed by 3D radiation therapy based on CT imaging 
which allows accurate localization of the tumour and 
critical  normal  organ  structures  for  optimal  beam 
placement and shielding. The aim is to deliver radia-
tion to the gross tumour volume (GTV), with a margin 
for microscopic tumour extension called the clinical 
target volume (CTV), and a further margin uncertain-
ties from organ motion and setup variations called the 
planning target volume (PTV) [16].  
Intensity modulated radiation therapy (IMRT) 
IMRT  allows  the  oncologist  to  create  irregu-
lar-shaped radiation doses that conform to the tumour 
whilst simultaneously avoiding critical organs. IMRT 
is  made  possible  through:  a)  inverse  planning  soft-
ware  and  b)  computer-controlled  intensi-
ty-modulation  of  multiple  radiation  beams  during 
treatment.  IMRT  is  now  available  in  many  clinical 
departments and can be delivered by linear accelera-
tors with static or dynamic multi-leaf collimators or 
tomotherapy  machines.  This  has  allowed  improve-
ments in the therapeutic ratio for several tumor sites, 
such as head and neck cancers [17], prostate cancers 
[18] and gynecological cancers [19].  
Image-guided radiotherapy (IGRT) 
As treatment margins become tighter and more 
conformal, the potential to miss tumour due to organ 
motion and patient setup variations become greater 
[20]. When critical structures are close to the tumour, 
a slight positional error may also lead to inadvertent 
radiation of the normal organs. IGRT allows the de-
tection  of  such  errors  by  information  acquired 
through pre-radiotherapy imaging which allows for 
correction. One such example is with daily cone-beam 
CT  scans  acquired  before  each  treatment  [21].  The 
improved accuracy has made dose escalation feasible 
[22],  and  this  has  allowed  an  improvement  in  the 
therapeutic ratio for several tumor sites, such as head 
and neck cancers [23] and prostate cancers [24].  
Stereotactic body radiation therapy (SBRT) 
The  above  technological  advancements  have 
enabled  SBRT,  which  precisely  delivers  very  high 
individual doses of radiation over only a few treat-
ment fractions to ablate small, well-defined primary 
and  oligometastatic  tumours  anywhere  in  the  body 
[25,  26].  Due  to  the  high  radiation  dose,  any  tissue 
immediately  adjacent  to  the  tumour  is  likely  to  be 
damaged. However as the amount of normal tissue in 
the high dose region is small and non-eloquent, clini-
cally significant toxicity is low [27]. SBRT has shown 
excellent  results  in  the  treatment  of  early  stage 
non-small cell lung cancer  in patients unfit for sur-
gery. Other tumours include in the prostate, head and 
neck, hepatic, renal, oligometastases, spinal and pan-
creatic [28, 29, 30].  
Types of radiation used to treat cancer: pho-
tons radiation (x-rays and gamma rays), which 
are widely used 
Photon beams carry a low radiation charge and 
have a much lower mass. X-rays and gamma rays are 
routinely used photons in radiation therapy to treat 
various cancers. X- rays and gamma rays are sparsely 
ionizing radiations, considered low LET (linear ener-
gy  transfer)  electromagnetic  rays  and  further  com-
posed of massless particles of energy are called pho-
tons.  X-rays  are  generated  by  a  device  that  excite 
electrons (e.g. cathode ray tubes and linear accelera-
tors), while gamma rays originate from the decay of 
radioactive substances (e.g.cobalt-60, radium and ce-
sium). 
Particle radiations (electron, proton and neu-
tron beams) 
 Electron beams are commonly used in everyday 
radiation therapy treatment and are particularly use-
ful to treat tumours close to a body surface since they 
do not penetrate deeply into tissues. External beam 
radiation therapy is also carried out with heavier par-
ticles such as: neutrons produced by neutron genera-
tors and cyclotrons; protons produced by cyclotrons Int. J. Med. Sci. 2012, 9 
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and  synchrotrons;  and  heavy  ions  (helium,  carbon, 
nitrogen,  argon,  neon)  produced  by  synchrocyclo-
trons  and  synchrotrons.  Proton  beams  are  a  newer 
form of particle beam radiation used to treat cancer. It 
can  offer  better  dose  distribution  due  to  its  unique 
absorption  profile  in  tissues,  known  as  the  Bragg’s 
peak,  allowing  deposition  of  maximum  destructive 
energy at the tumor site while minimizing the damage 
to healthy tissues along their path. These have partic-
ular  clinical  use  in  pediatric  tumors  and  in  adults 
tumors located near critical structures such as spinal 
cord and skull base tumors, where maximal normal 
tissue sparing is crucial [31]. Neutron beams are gen-
erated inside neutron generators after proton beams 
are deflected to a target. They have high LET and can 
cause more DNA damage than photons. The limita-
tions have been mainly due to difficulty in generating 
neutron particles as well as the construction of such 
treatment facilities.  
Particle radiation has higher LET than photons 
with higher biological effectiveness. Therefore, these 
forms of radiations may be more effective to the ra-
dioresistant cancers such as sarcomas, renal cell car-
cinomas, melanomas and glioblastoma [32]. However, 
equipment for production of particle radiation ther-
apy is considerably more expensive than for photons. 
The decreasing costs of cyclotrons are likely to result 
in a wider use of proton beam therapy in the future 
[33]. 
Biological aspects 
Biological effectiveness (cell killing) of radiation 
depends  on  the  linear  energy  transfer  (LET),  total 
dose,  fractionation  rate  and  radio-sensitivity  of  the 
targeted cells or tissues [34, 35]. Low LET radiation 
deposits relatively a small quantity of energy whilst 
high  LET  radiation  deposits  higher  energy  on  the 
targeted areas. Though radiation is directed to kill the 
tumor  cell,  it  is  inevitable  that  the  non-cancerous 
normal tissues surrounding the tumour also damaged 
by radiation. However, the goal of radiation therapy 
is to maximize the dose to tumour cells while mini-
mizing exposure to normal healthy cells [36].  
Radiation therapy works through in various 
ways to remove the cancer cells 
The  biological  target  of  radiation  in  the  cell  is 
DNA (Figure 1). 
1. Direct effects of radiation: Radiation can di-
rectly interact with cellular DNA and cause damage 
(Figure 2A).  
2. Indirect effects of radiation: The indirect DNA 
damage caused by the free radicals is derived from 
the ionization or excitation of the water component of 
the cells (Figure 2B).  
Double strand DNA breaks are irreparable and 
more responsible than the single strand DNA breaks 
for most of cell killing in cancer as well as surround-
ing normal cells. 
 
 
 
Figure 1. The biological target of radiation in the cell is 
DNA. Extensive damage to cancer cells DNA can lead to 
cell death. DNA  double-strand breaks (DSBs) are  more 
responsible for most cells killing, even a single DSB is suffi-
cient to kill a cell or disturb its genomic integrity by the 
radiation treatment.  
 
 
 
Figure 2. Radiation act directly or indirectly on the cellular 
DNA.  
 
 
Radiation therapy and cell death 
Radiation therapy can kill cancer cells by a vari-
ety of mechanisms. The main goal of radiation thera-
py  is  to  deprive  cancer  cells  of  their  multiplication 
potential and eventually kill the cancer cells. Cancer 
cells whose DNA is damaged beyond repair stop di-
viding and die. 
 However, the mechanism of cell death response 
to  irradiation  is  complex.  Thus,  identifying  the  im-Int. J. Med. Sci. 2012, 9 
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portance of radiation induced cell death and further 
mechanisms  involved  has  potential  clinical  implica-
tions for improving outcomes with radiation therapy. 
Types and characteristics of cell death 
Radiation  therapy,  like  most  anticancer  treat-
ments, achieves its therapeutic effect by inducing dif-
ferent  types  of  cell  death  [37]  (Figure  3).  Radiation 
therapy does not kill cancer cells right away. It takes 
hours, days or weeks of treatment before cancer cells 
start to die after which cancer cells continue dying for 
weeks to months after radiation therapy ends. 
 
 
 
Figure 3. Types of cell death induced by radiation. Radia-
tion mainly kills the cells either by apoptosis or mitotic 
catastrophe. 
 
 
 
Apoptosis: Programmed cell death or apoptosis 
is a major cell death mechanisms involved in cancer 
therapy and in radiation therapy in particular [38, 39, 
40]. Apoptosis is characterized by cell shrinkage and 
formation  of  apoptotic  bodies.  Mitochondria  play  a 
major role for the apoptotic cell death [41]. Blebbing of 
cell membrane is often seen with condensed chroma-
tin  with  nuclear  margination  and  with  DNA  frag-
mentation.  In  general,  the  cellular  membrane  of 
apoptotic cells remains intact. Induction of apoptosis 
in cancer cells plays an important role in the efficacy 
of radiation therapy [37, 42]. 
Mitotic cell death or Mitotic catastrophe: This 
type cell death occurs during or after aberrant mitosis 
(cell  division)  and  is  caused  by  mis-segregation  of 
chromosomes leading to formation of giant cells with 
aberrant nuclear morphology, multiple nuclei. Cells 
often have one or more micronuclei and with centro-
some over duplication [43, 44]. After irradiation, most 
of solid tumor cell death occurs predominantly as a 
result of aberrant mitotic events [45].  
The above two types of cell death account for the 
majority of ionizing radiation induced cell death. 
Necrosis: Cells visibly swell with breakdown of 
cell membrane. Cells have an atypical nuclear shape 
with  vacuolization,  non-condensed  chromatin  and 
disintegrated  cellular  organelles  along  with  mito-
chondrial  swelling  and  plasma  membrane  rupture 
followed by subsequent loss of intracellular contents 
[46].  
Following  radiation,  necrosis  is  seen  less  fre-
quently but does occur in cancer cell lines or tissues. 
Senescence: Senescence refers to a state of per-
manent  loss  of  cell  proliferative  capacity.  Senescent 
cells are viable but non-dividing, stop to synthesize 
DNA,  become  enlarged  and  flattened  with  an  in-
creased granularity. Senescence has been reported to 
occur in cancer cells following extensive cellular stress 
in  the  form  of  DNA  damage  induced  by  radiation 
treatment [47, 48] and later die mainly by the process 
of apoptosis.  
Autophagy:  Autophagy  is  a  more  recent  phe-
nomenon described. It is a form of cancer cell death in 
response  to  radiation.  Autophagy  is  a  genetically 
regulated  form  of  programmed  cell  death  in  which 
the  cell  digests  itself  that  involves  autophag-
ic/lysosomal compartment. It is characterized by the 
formation of double-membrane vacuoles in the cyto-
plasm, which sequester organelles such as condensed 
nuclear chromatin and ribosomes [49, 50]. 
Various genes and intracellular pathways have 
been reported to be involved in the different types of 
radiation induced cell death. Apoptosis has been as-
sociated  with  the  ATM-p53-Bax-Cytochrome 
c-Caspases  pathway  [51], whilst  mitotic  catastrophe 
involves the p53-Caspases-Cytochrome c cascade [52]. 
In  the  necrosis,  TNF  (alpha)  -PARP-JNK-Caspases 
pathway  [53]  is  involved  and  the 
MYC-INK4A-ARF-p53-p21 pathway has been impli-
cated  in  senescence  [54].  With  autophagy,  the 
PI3K-Akt-mTOR cascade is thought to be important 
[55]. Though most of these pathways are interrelated 
for radiation induced cancer cell death, much remains 
to be understood in the cell death pathways that gen-
erate  cancer  cell  tumorigenesis  and  radiation  treat-
ment resistance. However, the precise mechanism(s) 
responsible for radiation induced different mode  of 
cancer cell death have not been fully elucidated. In 
recent  years,  knowledge  is  rapidly  increasing  re-
garding the various molecular pathways involved in 
determining  cell  death  after  exposure  to  radiation. 
Areas of interest include studying the mechanisms of 
DNA damage response and repair, intracellular sig-Int. J. Med. Sci. 2012, 9 
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naling in response to single or fractionated radiation 
as well as the effects of radiation on the tumor mi-
croenvironment. With advances in genome sequenc-
ing,  tumor  profiling  should  allow  more  individual-
ized treatment with risk stratification approaches [56] 
and allow for a more accurate molecular targeted an-
ticancer approach of radiation therapy [10] in the next 
decade.  
Conclusions  
Radiation  remains  an  important  modality  for 
cancer  treatment  with  ongoing  efforts  towards  de-
signing new radiation treatment modalities and tech-
niques which continue to improve the survival and 
quality of life of cancer patients. With the improved 
clinical  outcomes  of  cancer  treatment,  minimizing 
radiation therapy related toxicities has also become a 
priority.  The  emergence  of  mechanistic  biological 
studies  together  with  improvements  in  radiation 
technology  has  improved  the  sparing  of  normal 
cells/tissues through dose fractionation and confor-
mal radiation techniques. Radiation is also being de-
livered in combination with molecular targeted ther-
apy with the aim of further improving the therapeutic 
ratio of the radiation treatment [10, 57, 58].  
Though  ionizing  radiation  remains  one  of  the 
most  effective  tools  in  the  therapy  of  cancer  cure, 
answers  to  a  number  of  questions  remain:  1.  What 
criteria drive the cancer cells in the selection of a par-
ticular  type  of  cell  death  pathway?  2.  How  does  a 
cancer cell switch from a recovery (repair) program to 
destructive cell death? 3. Ways to optimize the effec-
tiveness  of  radiation  therapy  in  combination  with 
other modalities of treatment? 4. Would it be possible 
to lower radiation therapy effects to normal tissues? 
Answers to these and other questions together with 
ongoing advancements in radiation therapy technol-
ogy and techniques will ultimately lead to continued 
improvement in cancer treatment. 
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